Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
- 5 August 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 74 (12), 1315-1333
- https://doi.org/10.1007/s40265-014-0267-8
Abstract
Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide. Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents are not effective against many strains, and carbapenems have played an important role in therapy. Recent trends show many infections are caused by carbapenem-resistant or even extensively drug-resistant (XDR) strains, for which effective therapy is not well established. Evidence to date suggests that colistin constitutes the backbone of therapy, but the unique pharmacokinetic properties of colistin have led many to suggest the use of combination antimicrobial therapy. However, the combination of agents and dosing regimens that delivers the best clinical efficacy while minimizing toxicity is yet to be defined. Carbapenems, sulbactam, rifampin and tigecycline have been the most studied in the context of combination therapy. Most data regarding therapy for invasive, resistant A. baumannii infections come from uncontrolled case series and retrospective analyses, though some clinical trials have been completed and others are underway. Early institution of appropriate antimicrobial therapy is shown to consistently improve survival of patients with carbapenem-resistant and XDR A. baumannii infection, but the choice of empiric therapy in these infections remains an open question. This review summarizes the most current knowledge regarding the epidemiology, mechanisms of resistance, and treatment considerations of carbapenem-resistant and XDR A. baumannii.This publication has 145 references indexed in Scilit:
- Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case-control studyClinical Microbiology & Infection, 2012
- Pharmacokinetics of Colistin in Cerebrospinal Fluid after Intraventricular Administration of Colistin MethanesulfonateAntimicrobial Agents and Chemotherapy, 2012
- Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistanceFEMS Microbiology Reviews, 2011
- The pmrCAB Operon Mediates Polymyxin Resistance in Acinetobacter baumannii ATCC 17978 and Clinical Isolates through Phosphoethanolamine Modification of Lipid AAntimicrobial Agents and Chemotherapy, 2011
- In Vivo Efficacy of Glycopeptide-Colistin Combination Therapies in a Galleria mellonella Model of Acinetobacter baumannii InfectionAntimicrobial Agents and Chemotherapy, 2011
- Overexpression of Resistance-Nodulation-Cell Division Pump AdeFGH Confers Multidrug Resistance in Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2010
- Acinetobacter baumannii 2002–2008: Increase of Carbapenem-Associated Multiclass Resistance in the United StatesMicrobial Drug Resistance, 2010
- Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patientsInternational Journal of Antimicrobial Agents, 2010
- Overexpression of the Naturally Occurring bla OXA-51 Gene in Acinetobacter baumannii Mediated by Novel Insertion Sequence IS Aba9Antimicrobial Agents and Chemotherapy, 2009
- Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*Critical Care Medicine, 2006